BROHAWN PZ ET AL: "Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures", LUPUS, vol. 28, no. 13, 29 October 2019 (2019-10-29), GB, pages 1524 - 1533, XP093057738, ISSN: 0961-2033, Retrieved from the Internet <URL:http://journals.sagepub.com/doi/full-xml/10.1177/0961203319885447> DOI: 10.1177/0961203319885447 (B1)

ERIC MORAND ET AL: "Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial", 23 October 2019 (2019-10-23), XP055767128, Retrieved from the Internet <URL:https://acrabstracts.org/abstract/efficacy-and-safety-of-anifrolumab-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus-results-of-the-second-phase-3-randomized-controlled-trial/> [retrieved on 20210120] (B1)

WO-A1-2020/165437 (B1)

RICHARD FURIE ET AL: "Anifrolumab, an Anti-Interferon-[alpha] Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus : ANIFROLUMAB IN MODERATE-TO-SEVERE SLE", ARTHRITIS & RHEUMATOLOGY (HOBOKEN), vol. 69, no. 2, 28 January 2017 (2017-01-28), US, pages 376 - 386, XP055652780, ISSN: 2326-5191, DOI: 10.1002/art.39962 (B1)

WO-A1-2017/031288 (B1)

RICHARD FURIE ET AL: "A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus", 23 October 2019 (2019-10-23), XP055767135, Retrieved from the Internet <URL:https://acrabstracts.org/abstract/a-phase-3-randomized-controlled-trial-of-anifrolumab-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus/> [retrieved on 20210120] (B1)